Different Mutation Frequencies and Spectra among Organs by N-Methyl-N-nitrosourea in rpsL (strA) Transgenic Mice

Yoshiyuki Shioyama,1,4 Yoichi Gondo,2 Kazuki Nakao3 and Motoya Katsuki3,5

1Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582. 2RIKEN Genomic Sciences Center, 2-14 Mudda-cho, Tatsuoka-ku, Yokohama 244-0084 and 3Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639

The frequencies and spectra of N-methyl-N-nitrosourea (MNU)-induced in vivo somatic mutations were determined in rpsL (strA) transgenic mice. The wild-type rpsL gene, which exhibits a streptomycin-sensitive (SmS) phenotype, was used as the rescue marker gene. Studies of mutation spectra among different organs and tissues were simplified using this system because of the short coding sequence (375 bp) of the rpsL gene. MNU administration to transgenic mice significantly elevated the mutation frequencies in various adult organs. Two distinctive patterns of mutation spectra were observed, depending on the organs tested. Mutations derived from labile organs (spleen and thymus) were predominantly G:C to A:T transitions, as expected for MNU mutagenesis. Stable organs like the liver and brain, however, carried many fewer G:C to A:T transitions but significantly more single base deletions, of which the spectrum was very similar to that of background mutations in the rpsL transgenic mice. This spectrum difference among more and less proliferating organs was confirmed by the predominant occurrence of G:C to A:T transitions in fetal liver cells exposed to transplacental MNU treatment. In addition, most (approximately 90%) of the G:C to A:T transitions induced by MNU were detected in the first nucleotide of some 5′-G-(C or G)-3′ sequences, many of which corresponded to the middle guanine residue of 5′-purine-G-(C or G)-3′ sequences. It is thus suggested that at particular sites, the neighboring bases in both the 5′ side and 3′ side seem to influence either the susceptibility to DNA damage or the ability to repair MNU-induced lesions.

Key words: Transgenic mouse — rpsL gene — Shuttle vector — Somatic mutation — N-Methyl-N-nitrosourea

Chemically induced or spontaneous tumors in various species and organs have mutations in oncogene(s) and/or suppressor oncogene(s). Therefore, it is very important to devise a rapid and easy method of detecting somatic mutations in vivo in mammals. Transgenic mice carrying an Escherichia coli shuttle plasmid vector with a mutation-monitoring marker gene are very useful for in vivo mutagenesis studies in mammals. Several transgenic mouse systems have been developed and reported.1–5 Two transgenic systems, Mutamouse6–9 and Big Blue2–4 have been well characterized and widely used.6–9 They are color-screening systems using lambda phage (λ) shuttle vectors that consist of the E. coli lacZ gene (Mutamouse) or lacI gene (Big Blue) as a mutation monitor gene. In order to increase the sensitivity and to reduce the labor-intensive work involved, several positive detection systems have recently been developed for in vivo mutagenesis assays.10–15

The rpsL (strA) transgenic mouse is a novel positive detection system using a plasmid shuttle vector pML4.14 The wild-type rpsL gene carries the dominant streptomycin-sensitive (SmS) phenotype. The shuttle vector pML4 consists of the rpsL gene, kanamycin resistance gene (KmR) and replication origin. In order to estimate the mutation frequencies using the rpsL transgenic mouse system, the shuttle vector is rescued from the transgenic genome by restriction and self-ligation and then is introduced into the appropriate E. coli host cells by electroporation. A part of the transformed E. coli cells are spread onto plates containing kanamycin (Km) and all the rest onto plates containing both Km and Sm. The ratio of the number of the KmR and SmR colonies to that of the KmR colonies is thus a measure of the mutation frequencies.14 In addition to this simplified detection system for in vivo mutations, studies on the mutation spectra of the monitor gene are much easier in the rpsL transgenic mouse than in other transgenic systems. Firstly, the coding sequence of the rpsL gene (375 bp) is much smaller than that of the lacI gene (about 1 kb) or the lacZ gene (about 3 kb). Secondly, since the shuttle vector is a plasmid DNA in the rpsL transgenic system, it can be directly used as a sequencing template. Mutation spectrum studies of the rpsL gene have also been conducted on E. coli.16

5 To whom correspondence should be addressed.
E-mail: katsuki@ims.u-tokyo.ac.jp
Transgenic mouse models allow us to analyze the mutations of various organs in the same mouse. This is one of the greatest advantages of transgenic systems. Therefore, by using transgenic systems, it is feasible to determine the tissue specificity of spontaneous or induced mutations. N-Methyl-N-nitrosourea (MNU) is an alkylating agent, which has been shown to induce G:C to A:T transitions by forming O\(^6\)-methylguanine adducts in prokaryotic and eukaryotic cells, probably through the mismatch pairing of O\(^6\)-methylguanine with thymidine during DNA replication.\(^{17-19}\) It has been reported that mutation frequencies were increased by MNU in a tissue-specific manner by using MNU-treated lacI transgenic mice and that the predominant mutations in MNU-treated mice were G:C to A:T transitions.\(^{20, 21}\) We herein describe MNU-induced mutations in various organs of not only adults but also fetuses of the rpsL transgenic mice. The mutation frequencies were increased in a tissue-specific manner, as reported,\(^{20, 21}\) but two distinctive patterns of mutation spectrum, dependent on the rate of the cell division, were observed for the first time.

MATERIALS AND METHODS

Transgenic mice One of the rpsL transgenic lines, HIT017\(^{14}\) was used. HIT017 carries approximately 350 copies of the pML4 shuttle plasmid vector hemizygotously in the haploid genome with a form of head-to-tail tandem arrangement.\(^{14}\) The HIT017 founder male mouse was crossed and propagated with nontransgenic (C57BL/6J×DBA/2J)F1 (BDF1) female mice. The rpsL hemizygous transgenic offspring were identified by Southern blot analyses as previously described.\(^{14}\) Only the transgenic mice were used for the subsequent mutagenesis analyses.

Mutagen treatments and tissue isolation MNU (Nakalai Tesque Inc., Kyoto) was resolved in a 0.1 M citrate buffer, pH 6.0 just prior to administration. When the transgenic mice were killed, all organs were immediately frozen in liquid nitrogen and stored at −80°C. They were thawed only once just prior to DNA isolation as described below.

Treatment of adult mice Pairs of one male and one female mouse, about 8 weeks of age, were treated daily with MNU (0, 10 or 40 mg/kg body weight) intraperitoneally for three consecutive days. Six mice were killed two weeks after the MNU treatment, and the brain, thymus, lung, liver and spleen from each mouse were isolated.

Treatment of fetuses In order to investigate the mutation frequencies in fetuses, 20 BDF1 oocytes were in vitro fertilized with a male HIT017 hemizygous transgenic mouse and transferred into the oviducts of pseudo-pregnant ICR female mouse. Two such pregnant ICR female mice were treated intraperitoneally with a single dose of MNU (0 or 75 mg/kg body weight) on day 9.5 of gestation. The fetuses were obtained from the pregnant female mice on day 18.5 of gestation. The liver and brain were isolated. The genotype of each fetus was determined by a Southern blot analysis of the DNA extracted from their limbs and tail. Two and three transgenic fetuses were obtained from the pregnant mice treated with MNU (0 and 75 mg/kg), respectively.

Genomic DNA preparation The detailed procedures of genomic DNA preparation for electroporation have been described previously.\(^{16}\) The genomic DNA was digested with restriction enzyme, BanII (TaKaRa, Tokyo), in order to excise the integrated shuttle vector at unit size. The BanII-digested DNA was then treated with T4 DNA ligase to self-circularize the transgene.\(^{14}\)

Mutagenesis assay The detailed procedures for the mutagenesis assay and the calculation of the mutation frequency have also been described previously.\(^{16}\) Briefly, the whole transgenic DNA after BanII- and T4 DNA ligase treatments was transformed into E.coli, RR1 [supE44, hsdS20, ara-14, proA2, lacY1, galk2, rpsL20, xyl-5, mtl-1] by electroporation with Cell Porator E. coli System (Gibco-BRL, Rockville, MD) according to the manufacturer’s instructions. After expression in the SOC medium, a small aliquot of the SOC culture was plated onto LB agar plates containing Km (50 µg/ml) while the rest was plated onto LB plates containing both Km (50 µg/ml) and Sm (100 µg/ml).

Sequencing Each mutant colony (Sm\(^8\) and Km\(^8\)) was independently transferred to 1 ml of fresh TB broth\(^{22}\) containing Km (final concentration of 50 µg/ml) in each well of a 24-well dish (Corning, Acton, MA). The dish was incubated in a moisture chamber at 37°C overnight under 100 rpm rotation to amplify the plasmid DNA. Then the plasmid DNA was extracted by the alkaline lysis method.\(^{22}\) The extracted plasmid DNA was suspended in 20 µl of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). To the 50 µl of plasmid DNA suspension, 0.5 µl of 1 mg/ml RNase (Sigma, St. Louis, MO) was added and the mixture was incubated for 5 min at room temperature. The DNA was then precipitated at 0°C by adding 30 µl of the PEG (20% polyethylene glycol, 2.5 M NaCl) solution and the pellet after centrifugation was rinsed with 1 ml of 70% ethanol. The DNA was resuspended in 15 µl of TE. Then, 5 µl of the DNA (approximately 1 g) was used as a sequencing template for amplification with a dideoxynucleotide chain termination sequencing kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. The DNA sequences were determined by using a 373A Autosequencer (Applied Biosystems, Foster City, CA). The primer DNAs for the sense and the antisense strands were oligonucleotides extending from positions −36 to −17 (5′-GTITFAGCAAGCAAAAGCTAA-3′)\(^{60}\) and +433 to +416 (5′-GGCATGGAATACTCGGTTG-3′) of the rpsL sequence, respectively. For the analysis of the promoter
region, an oligonucleotide from position −263 to −243 (5′-GCGCACATTTCCCCGAAAAGT-3′) was also used as a primer for the sense strand.

RESULTS

MNU treatment in adult mice  MNU administration to adult *rpsL* transgenic mice induced mutations in a dose-dependent manner, except in the brain. The mutation spectrum study showed that G:C to A:T transitions, which were expected to be induced by MNU administration, were predominantly observed in the spleen, thymus and lung, but not in the liver. The results for each organ are described below.

Spleen, thymus and lung  The average mutation frequencies in adult mice, that were treated with 40 mg/kg/day for three consecutive days and assayed two weeks after the administration, were 17.1 ± 1.0 × 10⁻⁵, 12.6 ± 1.9 × 10⁻⁵ and 11.2 ± 0.3 × 10⁻⁵ in the spleen, thymus and lung, respectively (Table I). Compared to the untreated controls, the mutation frequencies were increased by approximately 3-fold, 8-fold and 3-fold in spleen, thymus and lung, respectively (Table I). The mutation frequencies were significantly different between the treated and untreated mice (spleen, *t* = 5.56, d.f. (degree of freedom) = 2, *P* < 0.05; thymus, *t* = 7.73, d.f. = 2, *P* < 0.02; lung, *t* = 8.88, d.f. = 2, *P* < 0.02), in spite of the small sample sizes. The overall mutation frequencies increased dependent on the amount of MNU administered, as shown in Fig. 1. Furthermore, the mutation spectra were studied by the direct DNA sequencing of the whole *rpsL* coding sequence in the shuttle vector from randomly chosen mutant colonies on the Km and Sm plates. The predominant mutations in the MNU-treated mice were G:C to A:T transitions, accounting for 66.7% (22/33), 73.7% (14/19) and 59.1% (13/22) in the spleen, thymus and lung, respectively (Table II). On the other hand, more than half of all mutations derived from the untreated controls were frameshift mutations caused by a single base deletion, that accounted for 52.9% (9/17), 42.9% (3/7) and 61.5% (8/13) in the spleen, thy-

Table I. Mutation Frequencies (MF) in the *rpsL* Gene of pML4 Shuttle Vector Rescued from Adult and Fetal Organs after MNU Treatment

| Organs         | MNU dose (mg/kg)×days | No. of vectors screened (×10⁵)ᵃ | No. of mutants | Average MF±SD (×10⁻⁵) |
|---------------|-----------------------|---------------------------------|----------------|-----------------------|
| Spleen        | 0                     | 5.956                           | 27             | 5.1±2.9               |
|               | 10×3                  | 4.633                           | 30             | 6.4±0.5               |
|               | 40×3                  | 5.459                           | 95             | 17.1±1.0              |
| Thymus        | 0                     | 5.927                           | 8              | 1.6±0.6               |
|               | 10×3                  | 7.358                           | 19             | 2.6±2.1               |
|               | 40×3                  | 5.169                           | 68             | 12.6±1.9              |
| Lung          | 0                     | 5.994                           | 22             | 3.5±1.2               |
|               | 10×3                  | 4.611                           | 22             | 4.2±3.5               |
|               | 40×3                  | 2.946                           | 33             | 11.2±0.3              |
| Liver         | 0                     | 4.466                           | 29             | 6.3±0.8               |
|               | 10×3                  | 4.212                           | 56             | 13.6±3.2              |
|               | 40×3                  | 2.032                           | 51             | 25.0±2.9              |
| Fetal liver   | 0                     | 3.284                           | 21             | 6.3±0.4               |
|               | 75×1                  | 2.604                           | 89             | 24.8±19.0             |
| Brain         | 0                     | 2.308                           | 15             | 6.9±3.2               |
|               | 10×3                  | 3.058                           | 15             | 4.8±2.3               |
|               | 40×3                  | 3.437                           | 23             | 6.3±1.5               |
| Fetal brain   | 0                     | 3.609                           | 11             | 3.6±1.9               |
|               | 75×1                  | 7.863                           | 32             | 4.3±2.7               |

ᵃ The screened number of pML4 shuttle vectors was estimated from the number of Km⁸ colonies multiplied by the dilution ratio¹⁴. The mean of the counted Km⁸ colonies per one tested organ was 1190.9 (at least 219).
Mutations in rpsL Transgenic Mice

Mus and lung, respectively (Table II). It is noteworthy that such single base deletions of the rpsL gene were rarely observed in the mutagenesis studies of E. coli.16)

Liver As summarized in Table I, the average mutation frequency in MNU-treated adult mouse liver was also significantly increased by approximately 4-fold in comparison with untreated controls (t=8.81, d.f.=2, P<0.02). In spite of the significant induction of mutations by MNU, the mutation spectrum was rather similar to that of the untreated controls; namely, the predominant mutations were single base deletions in both the control mice (83.3%, 20/24) and the MNU-treated mice (77.4%, 24/31) (Table II).

Brain The average mutation frequency in the adult mouse brain was 6.3±1.5×10^{-5} in MNU-treated mice (Table I). Compared to the controls, there was no significant increase of mutation frequency (t=0.24, d.f.=2, P>0.5). The mutation spectrum was also similar between the control mice and the MNU-treated mice; the G:C to A:T transitions accounted for only 25.0% (4/16) and 22.2% (4/18) in the control mice and the MNU-treated mice, respectively (Table II).

MNU treatment in fetuses Compared to the untreated controls, the increase in average mutation frequency of the MNU-treated fetal liver was approximately 4-fold, although this was not statistically significant (t=1.69,
d.f. = 3, P > 0.10) (Table I). An analysis of the spectrum showed a drastic increase of G:C to A:T transitions (93.3%, 14/15) in comparison with the untreated controls (0%, 0/9) (Table III). In the MNU-treated fetal brain, the increase in the mutation frequency was small, but the majority of the mutations were G:C to A:T transitions (72.4%, 21/29) in contrast with the untreated controls (12.5%, 2/16) (Table III). The increases in the G:C to A:T transitions by MNU were statistically significant with P < 0.005 both in fetal liver ($\chi^2 = 20.1$, d.f. = 1) and fetal brain ($\chi^2 = 14.8$, d.f. = 1). These mutation spectra thus indicate a drastic difference of MNU mutagenesis between the adult and fetus in the liver and the brain.

**Distribution and incidence of MNU-induced G:C to A:T transitions**

The MNU-induced G:C to A:T transitions in the spleen, thymus and lung of adult mice and the fetal liver and brain described above are summarized in Fig. 2. The 84 G:C to A:T transitions were distributed at 12 sites of the *rpsL* sequences. Seven of the 12 sites corresponded to the first nucleotide of $5'$-G-(C or G)-3' with 92.9% (78/84) of G:C to A:T transitions. Of these, 78.2% (61/78) were observed at positions that corresponded to the middle guanine residue in $5'$-purine-G-(C or G)-3',

![Diagram](image_url)

Table III. Mutation Spectra of Fetal Organs with MNU Treatment

| Mutation class        | Untreated fetuses | MNU-treated fetuses |
|-----------------------|-------------------|---------------------|
|                       | Liver  | Brain  | Liver  | Brain  |
| Base substitution     | 44.4%  | 68.8%  | 93.3%  | 93.1%  |
| G:C→A:T              | 0      | 2      | 14\(^a\) | 21\(^a\) |
| Others                | 4      | 9      | 0      | 6      |
| Single base deletion  | 44.4%  | 25.0%  | 6.7%   | 6.9%   |
|                       | 4      | 4      | 1      | 2      |
| Deletion two or more bases | 0%  | 6.3%  | 0%     | 0%     |
|                       | 0      | 1      | 0      | 0      |
| Addition              | 11.1%  | 0%     | 0%     | 0%     |
|                       | 1      | 0      | 0      | 0      |
| Total                 | 9      | 16     | 15     | 29     |

This table shows the mutation spectra of the analyzed mutations of the liver and brain from two untreated fetuses and three MNU-treated fetuses.

\(^{a}\) P < 0.005 (liver, $\chi^2 = 20.1$, d.f. = 1; brain, $\chi^2 = 14.8$, d.f. = 1) in comparison with the untreated fetuses.

Fig. 2. The distributions and incidences of MNU-induced G:C to A:T transitions. G:C to A:T transitions derived from the spleen, thymus and lung of adult mice treated with 40 mg MNU/kg/day, and from the fetal liver and brain treated with 75 mg MNU/kg are depicted. The nucleotide positions are shown on the left of the sequence, with 1 being the first position of the start codon (ATG) and 375 being the third position of the termination codon (TAA). The mutations derived from the same organ of one mouse, namely, potentially clonally expanded mutations, are grouped in brackets [ ].

![Sequence Diagram](image_url)
such as positions 18, 95 and 251. Thus, these positions seem to be mutation “hot spots” for MNU. Another possibility would be the clonal expansion of a few founder mutations due to cell division during the two week post-treatment period. If all the identical DNA sequence changes observed in one organ of the same mouse were derived from one founder mutation, only 42 founder mutations would have given rise to the 84 G:C to A:T transitions. The putative founder mutations are indicated in brackets in Fig. 2. In this case, 85.7% of the founder mutations (36/42) were still observed at 5'-G-(C or G)-3', and 23 of them corresponded to the middle guanine residues in 5'-purine-G-(C or G)-3'. Thus, even if we assume that the identical mutations were the consequence of expansion from one mutation, there remain evident “hot spots” for MNU-induced mutagenesis. It is noteworthy that, among background mutations, a total of 13 G:C to A:T transitions were observed at 8 sites in the rpsL sequence (Fig. 3). Five of the 8 sites corresponded to the first nucleotide of 5'-G-(C or G)-3', and 76.9% of all the G:C to A:T transitions (10/13) in background mutations (if clonal expansions were considered, 72.7% or 8/11) were observed at these five sites. Four (position 3, 18, 83, and 251) of the 5 sites were the same as the positions at which the MNU-induced mutations were detected (see Fig. 2 and Fig. 3).

Spectra of the background mutations In the spleen, thymus, lung and liver, single base deletions were predominant among the mutations from the untreated mice (background mutations). In untreated adult and fetal brains, base substitutions were a major mutational type and consisted of 12/16 (75.0%) and 11/16 (68.8%), respectively, but single base deletions still accounted for a significant portion (25%) (Table II and Table III). Among all the background mutations, single base deletions comprised 51.0% (52/102). The next most common mutational type was base substitutions (40.1%, 41/102), and there were a few deletions of two or more bases (7.8%, 8/102). The distribution is shown in Fig. 3 for these single base deletions and base substitutions. Single base deletions were widely distributed in 27 sites of the rpsL sequence. Eighteen of 27 sites (66.7%) corresponded to sequences with a run of several identical residues; for example, at positions 127–132 (5'-AAAAAA-3') and 270–272 (5'-CCC-3'). Base substitutions, 23 transitions and 18 transversions,
were identified at 17 sites in the \( \text{rpsL} \) sequence. Interestingly, all 12 A:T to C:G transversions were identified at position 128, and seven of them concomitantly exhibited A:T to G:C transitions at position 16. Even considering clonal expansions, seven founder mutations were identified at position 128 and three founders of “double mutations” at both position 16 and 128 were observed.

In eight deletions of two or more bases, the numbers of deleted nucleotides were 2 bases (3/8), 3 bases (1/8), 4 bases (1/8), 15 bases (1/8) and 194 bases (2/8). In six of the 8 mutations, there were short direct repeats (i.e., 5′-CGCAA-3′ and 5′-CGTG-3′) flanking the deleted sequences, as if homologous recombination between the direct repeats had caused the deletion (data not shown).

**DISCUSSION**

In \( \text{rpsL} \) transgenic mice, we could positively detect in vivo somatic mutations, and subsequently characterize the mutational spectra by direct sequencing. We found clear differences in MNU mutagenicity among the tested organs, in the frequency as well as the spectrum. The mutation frequencies of MNU-treated mice were significantly increased in a dose-dependent manner, except in the brain, as has been reported. Since MNU is believed to be distributed efficiently to all tissues including the brain, the small response in the brain cannot be explained by the exposure level.

In the proliferating organs including the fetal liver and the brain, the predominant mutations were G:C to A:T transitions, as expected from previous studies. MNU is known to induce G:C to A:T transitions in \( \text{E. coli} \) and in eukaryotic cells in vitro as well as in vivo. On the other hand, the MNU-induced mutations detected in the less proliferating organs in this experiment, such as the adult liver, were predominantly single base deletions, which were also the major mutational type among the background mutations found in untreated \( \text{rpsL} \) transgenic mice. We thus conclude that cell division is necessary for the induction and fixation of G:C to A:T transition by MNU. This view is supported by the mutation spectra of the \( \text{rpsL} \) transgenic mice treated with a much higher dose of MNU with a minimum time of incubation. In a previous study, 100 mg/kg MNU was administered to the \( \text{rpsL} \) transgenic mice for 3 consecutive days. The brain, liver and spleen were immediately retrieved and tested. In this case, all the organs including the spleen exhibited the same mutation pattern as the background mutations (data not shown).

As regards the nature of single base deletions found in background mutations as well as in MNU-treated less-proliferating organs, two possibilities can be considered. DNA methylation in the mouse genome was minimal; details of this finding will be described elsewhere (Gondo, Shioyama and Katsuki, in preparation).

Predominance of frameshift mutations among the background mutations has also been reported in several other studies. For instance, frameshift mutations were predominantly observed in the gpt gene of a chromosomally integrated shuttle vector and human hprt cDNA integrated in mouse chromosomal DNA as background mutations. In contrast, the major background mutational events are base substitutions in such transgenic systems as the Mutamouse and Big Blue, and in the endogenous aprt gene of cultured CHO cells. The reporter gene used may influence the mutational spectra. Indeed, the pattern of mutation varies even within the lacI gene in \( \text{E. coli} \); for example, the ratio of base substitution to deletion/insertion mutation is 1.4:2 in the amino-terminal DNA binding domain, whereas deletion/insertion is increased by approximately 14-fold (if hotspots of frameshift mutations are deleted, approximately 2.5-fold) in the remaining domains. However, other factors, including the effect of chromosomal integration sites of monitor genes and the number of copies of transgenes, may also affect the spectrum of mutations.

It must be noted that the background mutation spectra in the \( \text{rpsL} \) transgenic mouse system were different from the spectra of \( \text{rpsL} \) mutations in the \( \text{E. coli} \) system; about half of \( \text{rpsL} \) mutations in \( \text{E. coli} \) were insertions of a transposon and almost all of the others were base substitutions. The difference in the mutational spectra between mice and \( \text{E. coli} \) suggests that the background mutations in our transgenic system are not likely to be artifacts, but probably represent authentic changes in the mouse DNA. Furthermore, we confirmed that the \( \text{ex vivo} \) artifact during enzymatic manipulation to retrieve the shuttle vectors from mouse genome was minimal; details of this finding will be described elsewhere.

The difference of mutation spectra between this study and previous studies using the Big Blue system might be due to the choice of the rescue method, selection system, and/or monitor gene. Recently, by using another transgenic system with gpt-based positive selection in a \( \lambda \) shuttle vector, about half of the background mutations were found to be short deletions/insertions, whereas eth-
or G)-3\′-purine-G-(C or G)-3′. A preference for the 5′-purine-G-3′ sequence in MNU- or MNNG (N-methyl-N′-nitro-N-nitrosoguanidine)-induced mutations was previously reported in eukaryotic cells\(^5\),\(^6\),\(^7\) and in E. coli\(^8\),\(^9\). Furthermore, the site specificity for the middle G in the 5′-purine-G-N-3′ sequence has been shown to be due primarily to the preferential MNU-reaction at this site to produce 6-methylguanine\(^4\). Our results are not only consistent with their previous studies, but also suggest that the 3′-flanking base may influence the mutability as well. In our case, the 3′-flanking base may affect the ability to repair rather than the susceptibility to DNA damage, because many G:C to A:T transitions (60–70%) among the background mutations were also observed at the first guanine residue of 5′-G-(C or G)-3′. However, the sequence 5′-G-(C or G)-3′ or 5′-purine-G-(C or G)-3′ seems to be a necessary but not a sufficient condition for hotspots of G:C to A:T transition induced by MNU, because there were many such sequences in which G:C to A:T transitions were not induced in the rpsL sequence.

Above all, the target organs of the MNU-induced base-substitutions described here and those of MNU-induced carcinogenesis\(^4\),\(^5\),\(^6\)–\(^5\)1 seem to be well correlated. The thymus\(^4\),\(^5\),\(^6\)–\(^8\) lung\(^9\),\(^10\) and forestomach\(^9\) are known to be labile target organs of MNU-induced tumorigenesis in the mouse. In addition, a partial hepatectomy study with MNU treatment induced hepatocarcinogenesis in the rat.\(^5\)

Various neoplasia were also induced by transplacental exposure to MNU in the rat.\(^5\)

The rpsL transgenic system has been proven to be a powerful tool in the study of in vivo mutagenesis. In particular, the results in the fetal liver clearly indicated that an increased proportion of mutations compared with the control was G:C to A:T transitions (Fig. 1). Such a sensitive analysis has become possible because of the quick and easy identification of many mutations by streptomycin selection and the availability of a mass sequencing system to analyze such mutations.

ACKNOWLEDGMENTS

We appreciate the excellent technical contributions by Toshiko Yokoyama, Yumiko Ikeda, Yoshiko Motegi, Aya Takeshita and Michie Takahashi. We also thank Minessuke Yokoyama and Takenori Hasegawa for their help in generating the transgenic mice; Kuniko Katsuki, Yusuke Sotomaru and Kazutaka Tsuru for maintaining the mice; Dr. Brian T. Quinn for help in the preparation of the manuscript; and especially Drs. Hisaji Maki and Mutuo Sekiguchi for their advice and for generously providing pML-4, and Drs. Sohei Kondo, Toshiyuki Norimura and Kouji Masuda for critical reading of the draft and for offering thoughtful suggestions. This work was supported by Grants-in-Aid for Scientific Research in Priority Areas, for Cancer Research, for Scientific Research and Developmental Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan, grants from the Ministry of Health and Welfare, Japan, and a grant to M. K. from the Science and Technology Agency, Japan. M. K. and Y. G. are recipients of Research Grants of the Princess Takamatsu Cancer Research Fund. Y. G. is also a recipient of funds from the Kato Memorial Bioresearch Foundation and the Fukuoka Cancer Society.

(Received January 5, 2000/Revised March 3, 2000/Accepted March 6, 2000)

REFERENCES

1) Gossen, J. A., de Leeuw, W. J. F., Tan, C. H. T., Zwarthoff, E. C., Berends, F., Lohman, P. H. M., Knoop, D. L. and Vijg, J. Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc. Natl. Acad. Sci. USA, 86, 7971–7975 (1989).
2) Short, J., Kohler, S. W., Huse, W. D. and Sorge, J. A. A transgenic model for the identification of genetic lesions. Fed. Proc., 8515a (1988).
3) Kohler, S. W., Provost, G. S., Fieck, A., Kretz, P. L., Bullock, W. O., Putman, D. L., Sorge, J. A. and Short, J. M. Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. Environ. Mol. Mutagen., 18, 316–321 (1991).
4) Kohler, S. W., Provost, G. S., Fieck, A., Kretz, P. L., Bullock, W. O., Sorge, J. A., Putman, D. L. and Short, J. M. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc. Natl. Acad. Sci. USA, 88, 7958–7962 (1991).
5) William, C. S., Glazer, P. M. and Malkевич, D. Lambda phage shuttle vectors for analysis of mutations in mammalian cells in culture and in transgenic mice. Mutat. Res., 220, 263–268 (1989).
6) Tinwell, H., Lefevre, P. A. and Ashby, J. Response of Muta Mouse lacZ/galE transgenic mutation assay to DMN: comparisons with the corresponding Big Blue. Mutat. Res., 307, 169–173 (1994).
7) Winegar, R. A., Lutz, L. H., Harmer, J. D., O’Loughlin, K. G. and Mirtsalis, J. C. Radiation-induced point mutations, deletions and micronuclei in lacI transgenic mice. Mutat. Res., 307, 479–487 (1994).
8) Tinwell, H., Lefevre, P. A. and Ashby, J. Mutation studies with dimethylnitrosamine in young and old lacI transgenic mice. *Mutat. Res.*, 307, 501–508 (1994).

9) Knüll, A., Jacobson, D. P., Kretz, P. L., Lundberg, K. S., Short, J. M. and Sommer, S. S. Spontaneous mutations in lacI-containing lysogens derived from transgenic mice: the observed patterns differ in liver and spleen. *Mutat. Res.*, 311, 57–67 (1994).

10) Gossen, J. A., Molijn, A. C., Douglas, G. R. and Vijg, J. Application of galactose-sensitive *E. coli* strains as selective hosts for lacZ plasmids. *Nucleic Acids Res.*, 20, 3254 (1992).

11) Gossen, J. A. and Vijg, J. A selective system for lacZ-phage using a galactose-sensitive *E. coli* host. *Biotechniques*, 14, 324–325 (1993).

12) Lundberg, K. S., Kretz, P. L., Provost, G. S. and Short, J. M. The use of selection in recovery of transgenic targets for mutation analysis. *Mutat. Res.*, 301, 99–105 (1993).

13) Martus, H. J., Dolle, M. E. T., Gossen, J. A., Boerrigter, M. E. T. I. and Vijg, J. Use of transgenic mouse models for studying somatic mutations in aging. *Mutat. Res.*, 338, 203–213 (1995).

14) Gondo, Y., Shioyama, Y., Nakao, K. and Katsuki, M. A novel positive detection system of in vivo mutations in rpsL (strA) transgenic mice. *Mutat. Res.*, 360, 1–14 (1996).

15) Nohmi, T., Katoh, M., Suzuki, H., Matsui, M., Yamada, M., Watanabe, M., Suzuki, M., Horiyaa, N., Ueda, O., Shibuya, T., Ikeda, H. and Sofuni, T. A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selection. *Environ. Mol. Mutagen.*, 28, 465–470 (1996).

16) Mo, J.-Y., Maki, H. and Sekiguchi, M. Mutational specificity of dnaE173 mutator associated with a defect in catalytic subunit of DNA polymerase III of *Escherichia coli*. *J. Mol. Biol.*, 222, 925–936 (1991).

17) Loechler, E. L., Green, C. L. and Essignmann, J. M. In vivo mutagenesis by O6-methylguanine built into a unique site in a viral genome. *Proc. Natl. Acad. Sci. USA*, 81, 6271–6275 (1984).

18) Ellison, K. S., Dogliotti, E., Connors, T. D., Basu, A. K. and Essignmann, J. M. Site-specific mutagenesis by O6-alkylguanines located in the chromosomes of mammalian cells: influence of the mammalian O6-alkylguanine-DNA alkyltransferase. *Proc. Natl. Acad. Sci. USA*, 86, 8620–8624 (1989).

19) Pesta, V., Gentil, A., Armier, J., Kyrtopoulos, S. A. and Sarasin, A. Mutagenesis by O6-methylG residues within codon 12 of the human Ha-ras protooncogene in monkey cells. *Nucleic Acids Res.*, 20, 4897–4901 (1992).

20) Provost, G. S., Kohler, S. W., Rogers, B., Matthews, C., Hamner, R. M., Putman, D. L. and Short, J. M. Mutational spectrum of methylisotrosourea in lambda/lacI B6C3F1 transgenic mice. *9th Annual Meeting of Genotoxicity and Environmental Mutagen Society, Durham, North Carolina*, abs. p.23 (1991).

21) Provost, G. S., Kretz, P. L., Hamner, R. T., Matthews, C. D., Rogers, B. J., Lundberg, K. S., Dycaico, M. J. and Sort, J. M. Transgenic systems for in vivo mutation analysis. *Mutat. Res.*, 288, 133–149 (1993).

22) Sambrook, J., Fritsch, E. F. and Maniatis, T. “Molecular Cloning, A Laboratory Manual,” 2nd Ed. (1989). Cold Spring Harbor Laboratory Press, NY, USA.

23) Frei, J. V., Swenson, D. H., Warren, W. and Lawley, P. D. Alkylation of deoxyribonucleic acid in vivo in various organs of C57BL mice by the carcinogens N-methyl-N-nitrosourea, N-ethyl-N-nitrosourea, and ethylmethanesulfonate in relation to induction of thymic lymphoma. *Biochem. J.*, 174, 1031–1044 (1978).

24) IARC. “Monographs on the Evaluation of Carcinogenic Risk to Some Chemicals to Man,” Vol. 7, pp. 111–140 (19XX). IARC, Lyon, France.

25) Richardson, K. C., Richardson, F. C., Crosby, R. M., Swenberg, J. A. and Skopek, T. R. DNA base changes and alkylation following in vivo exposure of *Escherichia coli* to N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea. *Proc. Natl. Acad. Sci. USA*, 84, 344–348 (1987).

26) Burns, P. A., Gordon, A. J. E. and Glickman, B. W. Mutational specificity of N-methyl-N-nitrosourea in the lac I gene of *Escherichia coli*. *Carcinogenesis*, 9, 1607–1610 (1988).

27) Moriwaki, S., Yagi, T., Nishigori, C., Imamura, S. and Takebe, H. Analysis of N-methyl-N-nitrosourea-induced mutations in a shuttle vector plasmid propagated in mouse O6-methylguanine-DNA methyltransferase-deficient cells in comparison with proficient cells. *Cancer Res.*, 51, 6219–6223 (1991).

28) Zhang, L. H. and Jenssen, D. Site specificity of N-methyl-N-nitrosourea-induced transition mutations in the hprt gene. *Carcinogenesis*, 12, 1903–1909 (1991).

29) Pegg, A. E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. *Cancer Res.*, 50, 6119–6129 (1990).

30) O’Toole, S. M., Pegg, A. E. and Swenberg, J. A. Repair of O6-methylguanine and O4-methylthymidine in F344 rat liver following treatment with 1,2-dimethylhydrazine and O6-benzyguanine. *Cancer Res.*, 53, 3895–3898 (1993).

31) Samson, L., Thomale, J. and Rajewsky, M. F. Alternative pathways for the in vivo repair of O6-alkylguanine and O4-alkylthymine in *Escherichia coli*: the adaptive response and nucleotide excision repair. *EMBO J.*, 7, 2261–2267 (1988).

32) Maher, V. M., Domoradzki, J., Bhattacharyya, N. P., Tsujimura, T., Corner, R. C. and McCormick, J. J. Alkylation damage, DNA repair and mutagenesis in human cells. *Mutat. Res.*, 233, 235–245 (1990).

33) Robbiano, L., Parodi, A., Venturelli, S. and Brambilla, G. Comparison of DNA alkylation, fragmentation, and repair in maternal and fetal tissues of pregnant rats treated with a single dose of ethyl methanesulfonate, ethyl-N-nitrosourea, N-nitrosodimetboxamine, and methyl-N-nitrosourea. *Teratog. Carcinog. Mutagen.*, 9, 157–166 (1989).

34) Ogita, T., Fukushima, H. and Nishimura, M. DNA strand breaks and death of thymocytes induced by N-methyl-N-
Mutations in rpsL Transgenic Mice

35) Fairbairn, L. J., Cowling, G. J., Dexter, T. M., Rafferty, J. A., Margison, G. P. and Reipert, B. Bcl-2 delay of alkylating agent-induced apoptotic death in a murine hemopoietic stem cell line. *Mol. Carcinog.*, **11**, 49–55 (1994).

36) Ashman, C. R. and Davidson, R. L. Sequence analysis of spontaneous mutations in a shuttle vector gene integrated into mammalian chromosomal DNA. *Proc. Natl. Acad. Sci. USA*, **84**, 3354–3358 (1987).

37) Ikehata, H., Akagi, T., Kimura, H., Akasaka, S. and Kato, T. Spectrum of spontaneous mutations in a cDNA of the human *hprt* gene integrated into chromosomal DNA. *Mol. Gen. Genet.*, **219**, 349–358 (1989).

38) DeJong P. T., Grosovsky, A. J. and Glickman, B. W. Spectrum of spontaneous mutations at the *aprt* locus of CHO cells: an analysis at the DNA sequence level. *Proc. Natl. Acad. Sci. USA*, **85**, 3499–3503 (1988).

39) Schapper, R. M., Danforth, B. N. and Glickman, B. W. Mechanisms of spontaneous mutagenesis: an analysis of the spectrum of spontaneous mutation in the *Escherichia coli lacI* gene. *J. Mol. Biol.*, **189**, 273–284 (1986).

40) Masumura, K., Matsui, M., Katoh, M., Horiya, N., Ueda, O., Tanabe, H., Yamada, M., Suzuki, H., Sofuni, T. and Nohmi, T. Spectra of gpt mutations in ethylnitrosourea-treated and untreated transgenic mice. *Environ. Mol. Mutagen.*, **34**, 1–8 (1999).

41) Lukash, L. L., Boldt, J., Pegg, A. E., Dolan, M. E., Maher, V. M. and McCormick, J. J. Effect of O6-alkylguanine-DNA alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-N'-nitro-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts. *Mutat. Res.*, **250**, 397–409 (1991).

42) Akagi, T., Hiromatsu, K., Iyehara, H., Kimura, H. and Kato, T. Specificity of mutations induced by N-methyl-N-nitrosourea in a cDNA of the *hprt* gene. *Carcinogenesis*, **14**, 725–729 (1993).

43) Burns, P. A., Gordon, A. J. E. and Glickman, B. W. Influence of neighbouring base sequence on N-methyl-N'-nitro-N-nitrosoguanidine mutagenesis in the *lacI* gene of *Escherichia coli*. *J. Mol. Biol.*, **194**, 385–390 (1987).

44) Burns, P. A., Gordon, A. J. E. and Glickman, B. W. Mutational specificity of N-methyl-N-nitrosourea in the *lacI* gene of *Escherichia coli*. *Carcinogenesis*, **9**, 1607–1610 (1988).

45) Richardson, F. C. and Richardson, K. K. Sequence-dependent formation of alkyl DNA adducts: a review of methods, results and biological correlates. *Mutat. Res.*, **233**, 127–138 (1990).

46) Frei, J. V. and Lawley, P. D. Thymomas induced by simple alkylating agents in C57BL/Cbi mice: kinetics of the dose response. *J. Natl. Cancer Inst.*, **64**, 845–856 (1980).

47) Chan, F. P., Ens, B. and Frei, J. V. Cytogenetics of murine thymic lymphomas induced in neonatal and adult mice. *Cancer Genet. Cytogenet.*, **4**, 337–344 (1981).

48) Maitra, S. C. and Frei, J. V. Organ-specific effects of DNA methylation by alkylating agents in the inbred Swiss mouse. *Chem. Biol. Interact.*, **10**, 285–293 (1975).

49) Anisimov, V. N. Age and dose-dependent carcinogenic effects of N-nitrosomethylurea administered intraperitoneally in a single dose to young and adult female mice. *J. Cancer Res. Clin. Oncol.*, **119**, 657–664 (1993).

50) Kaufman, W. K., Kaufman, D. G., Rice, J. M. and Wenk, M. L. Reversible inhibition of rat hepatocyte proliferation by hydrocortisone and its effect on cell cycle-dependent hepatocarcinogenesis by N-methyl-N-nitrosourea. *Cancer Res.*, **41**, 4653–4660 (1981).

51) Sukumar, S. and Barbacid, M. Specific patterns of oncogene activation in transplacentally induced tumors. *Proc. Natl. Acad. Sci. USA*, **87**, 718–722 (1990).